Fig. 2: Pharmacokinetic results.
From: First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors
a CYH33 and b its active metabolite I27 Concentration-Time Profiles (Mean ± SD) on Cycle 1 Day 1 (1 mg, n = 1; 5 mg, n = 1; 10 mg, n = 2; 20 mg, n = 5; 30 mg, n = 12; 40 mg, n = 3; 60 mg, n = 4); c CYH33 and d its active metabolite I27 Concentration-Time Profiles (Mean ± SD) on Cycle 1 Day 28 (1 mg, n = 1; 5 mg, n = 1; 10 mg, n = 2; 20 mg, n = 6; 30 mg, n = 9; 40 mg, n = 7; 60 mg, n = 2); e Pharmacodynamic results showing changes of FBG levels from baseline on Cycle 1 Day 8 (1 mg, n = 1; 5 mg, n = 1; 10 mg, n = 2; 20 mg, n = 6; 30 mg, n = 12; 40 mg, n = 20; 60 mg, n = 4). The box represents 25th, 50th, and 75th percentiles of observed values; the whiskers represent the minimum and maximum values; green dots represent individual values. hr hour, FBG fasting blood glucose, SD standard deviation.
